FDA says its review of abortion pill will continue into next year
FILE - A coordinator shows the medications and care kit sent out the clients at the Massachusetts Medication Abortion Access Project, May 13, 2025, in Somerville, Mass. (AP Photo/Charles Krupa, File)
Credit: AP Photo/Charles Krupa
(AP Photo/Charles Krupa, File)
WASHINGTON (AP) — The Food and Drug Administration says its ongoing safety review of the nation’s main abortion pill will continue into next year, a timeline that was quickly condemned by abortion opponents hoping to see the drug’s use curtailed.
The FDA gave a court-ordered update on its progress in a legal filing late Wednesday, providing the first substantive information about the controversial reevaluation ordered by Health Secretary Robert F. Kennedy Jr.
Mifepristone was first approved by the FDA in 2000. The agency has repeatedly reaffirmed the pill’s safety and effectiveness over the years, in addition to easing a number of restrictions on the drug, including dropping a requirement that it be dispensed in person.
But since President Donald Trump returned to the White House, anti-abortion groups and their allies in Congress have pushed the administration to revisit the pill, in the hopes of restricting its use.
The FDA said in its filing that it expects to complete a safety study of the pill by mid-December this year. A report on the findings is expected “no later than March 2027,” after which the agency will decide whether to impose new restrictions or other changes on the drug’s use.
Gavin Oxley of Americans United for Life, an anti-abortion group, criticized the move as a lack of “true leadership” by Trump administration officials.
“The administration continues to find itself on the wrong side of women’s health, clearly uninterested in mitigating the ongoing harms caused by the abortion pill,” Oxley said.
The two-drug regimen of mifepristone, combined with a second drug misoprostol, is the most common form of abortion in the U.S.
The FDA was directed to provide the latest update by a federal appeals court in New Orleans, which is overseeing a case brought by the state of Louisiana alleging that mail-delivery of mifepristone undermines the state’s abortion ban. It’s one of several state lawsuits related to mifepristone winding their way through the courts.
___
The Associated Press’ health and science coverage receives financial support from the AP Fund for Journalism and private foundations. AP is solely responsible for all content. Find AP’s standards for working with philanthropies, a list of supporters and funded coverage areas at AP.org.





Comments
0 Comments